As GLP-1 medications have become a cultural phenomenon and gained associated market share, the role of legacy non-GLP anti-obesity drugs has become less clear. While some prescribing may be shifting toward GLP-1 therapies, cost, coverage restrictions and contraindications would support continued utilization of non-GLP anti-obesity medications in certain patient populations. Examining trends across these drug classes provides insight into how the proliferation of GLP-1 therapies is influencing, and potentially replacing, treatment patterns for legacy obesity products and changing the approach to weight management writ large.
Read the full article: GLP-1 Therapy Growth Has Reshaped Anti-Obesity Prescribing //
Source: https://www.trillianthealth.com/market-research/studies/glp-1-therapy-growth-has-reshaped-anti-obesity-prescribing